SGLT2 inhibition improves coronary flow velocity reserve and contractility: role of glucagon signaling
Abstract Background SGLT2 inhibitors, a T2DM medication to lower blood glucose, markedly improve cardiovascular outcomes but the underlying mechanism(s) are not fully understood. SGLT2i’s produce a unique metabolic pattern by lowering blood glucose without increasing insulin while increasing ketone...
Na minha lista:
| Principais autores: | , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BMC
2024-11-01
|
| Serier: | Cardiovascular Diabetology |
| Fag: | |
| Online adgang: | https://doi.org/10.1186/s12933-024-02491-w |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|
